ID

42334

Descrição

Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT01316224

Link

https://clinicaltrials.gov/show/NCT01316224

Palavras-chave

  1. 15/06/2021 15/06/2021 -
  2. 15/06/2021 15/06/2021 -
Titular dos direitos

AbbVie (prior sponsor, Abbott)

Transferido a

15 de junho de 2021

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Psoriatic Arthritis in Psoriasis NCT01316224

Eligibility Psoriatic Arthritis in Psoriasis NCT01316224

Inclusion Criteria
participant has a documented clinical diagnosis of psoriasis, as determined by participant interview of his/her medical history and confirmation of diagnosis through physical examination by the investigator
participant has indication of psoriasis systemic therapy
if female, participant is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control: condoms, sponge, foams, jellies, diaphragm or intrauterine device (iud)
contraceptives (oral or parenteral) for three months (90 days) prior to study drug administration
a vasectomized partner
total abstinence from sexual intercourse
able and willing to give written informed consent and comply with the requirements of the study protocol
Exclusion Criteria
participants who have active infections
participants enrolled in another study or clinical trial
any condition that according to the criteria of the participating investigator represents an obstacle for study conduction and/or participants to an unacceptable risk
history of active tuberculosis (tb), histoplasmosis or listeriosis

Similar models

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial